A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain
- Conditions
- Post Operative Dental Pain
- Interventions
- Drug: Placebo to diclofenac potassium
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 328
- Registration Number
- NCT02476422
- Locations
- 🇺🇸
Novartis Investigative Site, Austin, Texas, United States
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 772
- Registration Number
- NCT02474069
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT02474082
- Locations
- 🇩🇪
Novartis Investigative Site, Stade, Germany
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
- Conditions
- Hepatic Impairment
- Interventions
- Drug: INC280
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02474537
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
- Conditions
- Chronic Severe Plaque-type Psoriasis
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT02471144
- Locations
- 🇬🇧
Novartis Investigative Site, Scunthorpe, United Kingdom
Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 181
- Registration Number
- NCT02470403
- Locations
- 🇺🇸
Novartis Investigative Site, Lincoln, Nebraska, United States
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT02468674
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: INC280 single agent
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT02468661
- Locations
- 🇺🇸
Henry Ford Hospital SC, Detroit, Michigan, United States
🇺🇸Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States
🇺🇸University of California Irvine Medical Center Chao Family SC, Orange, California, United States
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
- Conditions
- Heart Failure With Reduced Ejection Fraction (HF-rEF)
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT02468232
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
- Conditions
- Cushing's SyndromeEctopic Corticotropin SyndromeAdrenal AdenomaAIMAHPPNADAdrenal Carcinoma
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02468193
- Locations
- 🇯🇵
Novartis Investigative Site, Chiba, Japan